Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …

Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the
treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie …

Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a wide range of
tumor-induced alterations, which affect both the innate and adaptive arms of the immune …

Despite the advanced age at onset, chronic lymphocytic leukemia (CLL) shortens the life
expectancy of the majority of newly diagnosed patients. The management of elderly patients …

Highlights•Hematological malignancies comprise 1.2 million new cases annually
worldwide.•Current treatment options are limited by cancer cell resistance and relapse …

The CLL disease course is heterogeneous with many patients never requiring treatment and
some having very aggressive rapid onset disease. Innate and adaptive immune …

Hematopoietic stem cell transplantation (HSCT) is the only established potentially curative
treatment option for chronic lymphocytic leukemia (CLL) to date. However, this approach is …

Therapeutic strategies targeting the programmed cell death-ligand 1/programmed cell death-
1 pathway have shown significant responses and good tolerability in solid malignancies …

Chronic lymphocytic leukaemia (CLL) is a common lymphoid malignancy characterized by
the expansion and progressive accumulation of mature autoreactive B lymphocytes. The …

Summary del17p-and/or p53 abnormalities are negative predictive factors for response to
therapy and survival. These abnormalities can be partly overcome by treatment with the anti …